Related Experiment Video

Updated: Oct 4, 2025

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs
07:09

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs

Published on: February 18, 2022

2.0K

SGLT2 Inhibitors in Older Adults with Heart Failure with Preserved Ejection Fraction

Julie Hias1,2, Laura Hellemans1,2, Karolien Walgraeve1

  • 1Pharmacy Department, University Hospitals Leuven, Leuven, Belgium.

Drugs & Aging
|February 4, 2022
PubMed

Insights

Empagliflozin is the first therapy to significantly improve outcomes in older adults with heart failure with preserved ejection fraction (HFpEF). This finding, from the EMPEROR-Preserved trial, reduces hospitalizations for HFpEF patients.

Area of Science:

  • Cardiology
  • Geriatrics
  • Pharmacology

Background:

  • Heart failure with preserved ejection fraction (HFpEF) is common in older adults.
  • Few therapies have demonstrated clinical benefit in HFpEF.
  • Heart failure with reduced ejection fraction (HFrEF) has multiple effective treatments.

Purpose of the Study:

  • To analyze the impact of empagliflozin on older adults with HFpEF.
  • To translate findings from the EMPEROR-Preserved trial to clinical practice for elderly HFpEF patients.
  • To focus on empagliflozin's effect on heart failure-related and all-cause hospitalizations.

Main Methods:

  • Review of the EMPEROR-Preserved trial data.
  • Comparison of EMPEROR-Preserved findings with previous HFpEF and HFrEF trials.
  • Discussion of ongoing clinical trials in the HFpEF landscape.

Main Results:

  • Empagliflozin is the first therapy to show significant clinical outcome improvement in HFpEF.
  • The study focuses on reducing hospitalizations in older adults with HFpEF.
  • Empagliflozin demonstrated a positive impact on patient trajectory in the elderly HFpEF population.

Conclusions:

  • Empagliflozin offers a new therapeutic option for older adults with HFpEF.
  • The EMPEROR-Preserved trial results are crucial for managing HFpEF in the elderly.
  • Further research and ongoing trials will continue to shape HFpEF treatment strategies.

More Related Videos

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

3.5K
Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF03:42

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF

Published on: March 29, 2024

1.7K

Related Concept Videos

Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
39
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
550
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
782
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
460
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
519
Drug Dosing: Geriatric Patients01:15

Drug Dosing: Geriatric Patients

Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
11